Search

Displaying results 4881 - 4890 of 10000 in total
  1. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. … The expression of the endogenous AX200 protein in the brain is increased after brain damage.

  2. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  3. Drug

    Maytansine

    go.drugbank.com/drugs/DB19582
    Investigational

    Maytansine is a small molecule drug. Maytansine is under investigation in clinical trial NCT04189211 (A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients). … Maytansine has a monoisotopic molecular weight of 691.29 Da.

  4. Drug

    Bevasiranib

    go.drugbank.com/drugs/DB06642
    Investigational

    Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Rheinanthrone

    go.drugbank.com/drugs/DB13175
    Experimental

    Rheinanthrone is the active metabolite of senna glycoside [DB11365] known for its laxative effect [A19235]. It is commonly produced by plants of the Rheum species [L772].

  6. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  7. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation

  8. Drug

    Dabigatran

    go.drugbank.com/drugs/DB14726
    ApprovedInvestigational

    Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

    Categories: Factor Xa Inhibitors, Direct factor Xa inhibitors
  9. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. … [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Edivoxetine

    go.drugbank.com/drugs/DB09184
    Investigational

    Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.